anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Accurate variant classification and relaying reclassified results to patients is critical for hereditary cancer care delivery. Over a 5- to 10-year period, 6%-15% of variants undergo reclassification. As the frequency of reclassifications increases, the issue of whether, how, when, and which providers should recontact patients becomes important but remains contentious.
METHODS: The authors used inductive thematic analysis to analyze open-ended comments offered by oncologists and genetic counselors (GCs) from a large national survey.
RESULTS: Of the 634 oncologists and cancer GCs, 126 (20%) offered substantive free-text comments. Four thematic areas emerged: 1) ambiguity over professional responsibility to recontact, 2) logistical challenges with recontact, 3) importance of inter-institutional communication, and 4) suggested solutions. Some oncologists felt that laboratories, not them, are responsible for recontact; others believed that ordering providers/GCs were responsible; GCs readily acknowledged their own responsibility in recontact but added important caveats. Besides the lack of up-to-date patient contact information, providers raised unique challenges with recontact: financial instability of laboratories, lack of clinical resources, contacting family members, and accumulating burden of reclassifications. There were numerous calls for developing practice guidelines on prioritizing variants for recontact and discussion on whether duty for recontact may be fulfilled via unidirectional, low touch modalities. Potential solutions to recontact including national databases and patient facing databases were discussed.
CONCLUSIONS: The authors confirm previous themes of stakeholder opinions and add previously unreported contextual details to qualify those themes. Clarifying provider responsibilities through professional guidelines for reclassification and recontact addressing the subthemes identified here will better serve all constituencies.
Subjects randomized to night-time supplemental oxygen will complete an overnight oxygen titration protocol in the clinical research unit. Initially, subjects will receive 0.5 liters oxygen (O2)/min; the delivery rate will then be increased by 0.5 l/min until oxygen saturation (SaO2) is ≥88%. The optimal O2 delivery rate determined during this study will be used for the intervention. The oxygen concentrators used at home will record cumulative hours of use to provide an objective measure of adherence (monitored weekly). Compliance will be defined as ≥6 h average use per night..
The intervention includes Docosahexaenoic acid - 800mg/day per day provided in two 400 mg capsules. The intervention group as well as the active comparator group will be given 1-200 mg/capsule per day of DHA that is a common amount in prenatal vitamins.
Anorexia nervosa (AN) mainly affects young people, especially young women. AN is one of the most lethal psychiatric disorders. Treatment often proves to be very difficult, and AN course is frequently chronic. Specific pharmacological therapies for AN are lacking. Recent studies have shown that metabolic alterations play a great role in the etiology and pathogenesis of AN. An important metabolic alteration playing a role in the etiology and pathogenesis of AN is the hormone leptin. Patients with AN show hypoleptinemia. The role of hypoleptinemia in the neuroendocrine adaptation to starvation seems to induce emotional, cognitive, and behavioral symptoms of AN. From a theoretical point of view, pharmacotherapy augmenting leptin levels in patients with AN have a great therapeutic potential. Recently, positive effects with experimental administration of subcutaneous metreleptin in few young patients with severe AN have been observed. Importantly, no side effects have been observed. For all these reasons, the present study will investigate - with a double blind design - the therapeutic effect of metreleptin in patients with AN. Metreleptin will be administrated to 50 AN-inpatients: 25 patients will receive verum and 25 will receive placebo during 14 days. Primary objectives of this study are the amelioration of mood and weight. Secondary objectives are the investigation of functional brain connectivity, AN symptoms, as well as hematologic, blood chemistry and neuroendocrinological hormones.
Methods and systems for managing patient health data are provided. A patient data tracking system is provided that aggregates patient data to create one or more patient data sets. The system analyzes and/or sorts the patient data set(s) to selectively provide information to different entities. The patient data may be secured such that the patient data set(s) are stored and/or disseminated in compliance with one or more applicable governmental or organizational regulations. As one example, the system can provide targeted information to a physician and healthcare organization that can help the physician and healthcare organization direct a patient's pain management therapy, develop treatment protocols for a patient population, or the like. The platform may use one or more dashboards to disseminate targeted information to the different entities. The dashboards may present information regarding an individual patient or one or more patient populations, e.g., aggregate patient population data or trends.
Headache, blurring of vision, confusion, drowsiness, syncope, fatigue, edema, thrombophlebitis, hematemesis, diarrhea, and pain. These did not appear to be dose related and were not unequivocally drug related. They may have been due to the primary or metastatic disease processes. Malaise and asthenia have been reported as part of post-marketing surveillance. Bladder fibrosis/contraction has been reported with intravesical administration (see PRECAUTIONS). 

To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Individuals in SHAM continuous airway positive pressure arm will use CPAP (model S7-Resmed®) with expiratory relief and nasal mask. The Sham-CPAP consists of a modified CPAP so that the pressure in the mask was less than 1 cm H2O. In this study, the Sham-CPAP equipment includes an increase in the expiratory orifice of the CPAP mask to eliminate airflow resistance, and a resistor with a small orifice was placed between the CPAP and the circuit. The noise produced by the ventilator and the airflow through the mask will be very similar to that of the effective CPAP. The diameter of the expiratory orifice was 10 cm H2O, and a 4 mm diameter resistor was placed between the trachea and the CPAP flow generator.
BACKGROUND: Breast cancer (BC) is a great clinical challenge because of its aggressiveness and poor prognosis. Zinc Finger Protein 64 (ZFP64), as a transcriptional factor, is responsible for the development and progression of cancers. This study aims to investigate whether ZFP64 regulates stem cell-like properties and tumorigenesis in BC by the glycolytic pathway.
RESULTS: It was demonstrated that ZFP64 was overexpressed in BC specimens compared to adjacent normal tissues, and patients with high ZFP64 expression had shorter overall survival and disease-free survival. The analysis of the association of ZFP64 expression with clinicopathological characteristics showed that high ZFP64 expression is closely associated with N stage, TNM stage, and progesterone receptor status. Knockdown of ZFP64 suppressed the viability and colony formation capacity of BC cells by CCK8 and colony formation assays. The subcutaneous xenograft models revealed that ZFP64 knockdown reduced the volume of formatted tumors, and decreased Ki67 expression in tumors. The opposite effects on cell proliferation and tumorigenesis were demonstrated by ZFP64 overexpression. Furthermore, we suggested that the stem cell-like properties of BC cells were inhibited by ZFP64 depletion, as evidenced by the decreased size and number of formatted mammospheres, the downregulated expressions of OCT4, Nanog, and SOX2 proteins, as well as the reduced proportion of CD44+/CD24- subpopulations. Mechanistically, glycolysis was revealed to mediate the effect of ZFP64 using mRNA-seq analysis. Results showed that ZFP64 knockdown blocked the glycolytic process, as indicated by decreasing glycolytic metabolites, inhibiting glucose consumption, and reducing lactate and ATP production. As a transcription factor, we identified that ZFP64 was directly bound to the promoters of glycolysis-related genes (ALDOC, ENO2, HK2, and SPAG4), and induced the transcription of these genes by ChIP and dual-luciferase reporter assays. Blocking the glycolytic pathway by the inhibition of glycolytic enzymes ENO2/HK2 suppressed the high proliferation and stem cell-like properties of BC cells induced by ZFP64 overexpression.
CONCLUSIONS: These data support that ZFP64 promotes stem cell-like properties and tumorigenesis of BC by activating glycolysis in a transcriptional mechanism.
Implantation of IBS in patients with coronary artery lesions. All the subjects will be assigned to cohort 1 (n=30) and cohort 2 (n=15).
Mefenamic acid has analgesic, anti-inflammatory, and antipyretic properties.

The mechanism of action of mefenamic acid, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). 

Mefenamic acid is a potent inhibitor of prostaglandin synthesis in vitro. Mefenamic acid concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because mefenamic acid is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.
Significant numbers of people with HIV/AIDS seek spiritual or "psychic" treatment. Distant healing could potentially be of benefit to large numbers of HIV/AIDS patients, as it is widely available and requires no travel or other activity on the part of the patient. However, the treatment can be costly and has not yet been proven effective in a controlled clinical trial. This study will evaluate the efficacy of distant healing in patients with HIV/AIDS.

Participants in this study will be randomly assigned to either the distant healing group or a control group. All participants will have hour-long study visits at entry and Months 6 and 12. At study visits, participants will complete a demographic questionnaire, self-report health and symptom inventory, quality of life assessment, and profile of mood states. Blood will be drawn at each study visit.
BACKGROUND: Infections are responsible for approximately 13% of cancer cases worldwide and many of these infections can be prevented by vaccination. Human papillomavirus (HPV) and hepatitis B virus (HBV) are among the most common infections that cause cancer deaths globally, despite effective prophylactic vaccines being available. This analysis aims to estimate the global burden and economic impact of vaccine-preventable cancer mortality across World Health Organization (WHO) regions.
METHODS: The number of deaths and years of life lost (YLL) due to five different vaccine-preventable cancer forms (oral cavity, liver, laryngeal, cervical, and oropharyngeal cancer) in each of the WHO regions (African, Eastern Mediterranean, European, the Americas, South-East Asia Pacific, and Western Pacific) were obtained from the Institute for Health Metrics Evaluation global burden of disease dataset. Vaccine-preventable mortality was estimated considering the fraction attributable to infection, to estimate the number of deaths and YLL potentially preventable through vaccination. Data from the World Bank on GDP per capita were used to estimate the value of YLL (VYLL). The robustness of these results was explored with sensitivity analysis. Given that several Epstein-Barr virus (EBV) vaccines are in development, but not yet available, the impact of a potential vaccine for EBV was evaluated in a scenario analysis.
RESULTS: In 2019, there were 465,740 potentially vaccine-preventable cancer deaths and 14,171,397 YLL across all WHO regions. The estimated economic impact due to this mortality was $106.3 billion globally. The sensitivity analysis calculated a range of 403,025-582,773 deaths and a range in productivity cost of $78.8-129.0 billion. In the scenario analysis EBV-related cancer mortality increased the global burden by 159,723 deaths and $32.4 billion.
CONCLUSION: Overall, the findings from this analysis illustrate the high economic impact of premature cancer mortality that could be potentially preventable by vaccination which may assist decision-makers in allocating limited resources among competing priorities. Improved implementation and increased vaccination coverage of HPV and HBV should be prioritized to decrease this burden.
PROBLEM TO BE SOLVED: To easily obtain the subject compound as an intermediate for the synthesis of naphthyridone carboxylic acid including trovafloxacin, by reducing a specific compound in the presence of iron and an organic solvent under an acidic condition to form a specific compound and then acylating the compound with an acylating agent. SOLUTION: This compound of formula III is obtained by reducing a compound of formula I (R<1> is benzyl) in the presence of iron and an organic solvent under an acidic condition to form the corresponding compound of formula II, which, preferably without isolation, is then acylated with an acylating agent of the formula R<2> C(O)X [R<2> is a 1-6C alkyl, trifluoromethyl or a (substituted) phenyl; X is an eliminable group). The organic solvent is a 1-6C alcohol (e.g. ethanol) or an ether (e.g. tetrahydrofuran). The acidic condition is afforded by the use of a mineral acid (e.g. hydrochloric acid) or an organic acid (e.g. acetic acid).
Dose escalation study. Part A) Gemcitabine dose escalation. Part B) L19IL2 dose escalation.
Transforming growth factor β (TGF-β) signaling is a core pathway of fibrosis, but the molecular regulation of the activation of latent TGF-β remains incompletely understood. Here, we demonstrate a crucial role of WNT5A/JNK/ROCK signaling that rapidly coordinates the activation of latent TGF-β in fibrotic diseases. WNT5A was identified as a predominant noncanonical WNT ligand in fibrotic diseases such as systemic sclerosis, sclerodermatous chronic graft-versus-host disease, and idiopathic pulmonary fibrosis, stimulating fibroblast-to-myofibroblast transition and tissue fibrosis by activation of latent TGF-β. The activation of latent TGF-β requires rapid JNK- and ROCK-dependent cytoskeletal rearrangements and integrin αV (ITGAV). Conditional ablation of WNT5A or its downstream targets prevented activation of latent TGF-β, rebalanced TGF-β signaling, and ameliorated experimental fibrosis. We thus uncovered what we believe to be a novel mechanism for the aberrant activation of latent TGF-β in fibrotic diseases and provided evidence for targeting WNT5A/JNK/ROCK signaling in fibrotic diseases as a new therapeutic approach.
BACKGROUND: The desmoplastic reaction is considered a promising prognostic parameter for colorectal cancer. However, intermediate desmoplastic reaction is characterized by sizeable stromal heterogeneity, including both small amounts of keloid-like collagen (KC) in the fibrotic stroma and thick tufts of KC circumferentially surrounding cancer nests and occupying most of the fields of view. The present study aimed to evaluate the diagnostic and prognostic significance of KC histophenotyping with a quantitative visual assessment of its presence in the stroma of the invasive margin of TNM (The "tumor-node-metastasis" classification) stage II/III colorectal cancer (CRC).
METHODS AND RESULTS: 175 resected tumors from patients with TNM stage II/III CRC were examined. Keloid-like collagen was assessed according to Ueno H. criteria. KC was assessed at the primary tumor invasive margin using Hematoxylin & Eosin and Masson's trichrome staining. The cut-off point for KC was examined using "the best cutoff approach by log-rank test." Using a cutoff point of 30%, we histologically divided fibrous stroma in the invasive area into two groups: "type A"-KC ≤ 0.3 and "type B"-KC>0.3. Type A stroma was observed in 48% of patients, type B-in 52%. The association between collagen amount and 5-year recurrence-free survival (5-RFS) was assessed using Cox regression analysis. Kaplan-Meier analysis and log-rank tests were used to assess the significance of survival analysis. Analysis of categorical variables showed that increased KC in CRC stroma predicted adverse outcomes for 5-RFS (hazard ratio [HR] = 3.143, 95%, confidence interval [CI] = 1.643-6.012, p = 0.001). Moreover, in Kaplan-Meier analysis, the log-rank test showed that type B exhibited worse 5-RFS than type A (p = 0.000).
CONCLUSION: KC is an independent predictor of 5-year overall and RFS in patients with TNM stage II/III CRC treated with surgery, with worse survival rates when the amount of KC increases by >30%.
BACKGROUND: Dupilumab, an anti-IL4 receptor-α monoclonal antibody, was the first biologic to be approved in Canada for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). In phase III clinical trials, it has demonstrated to be effective in reducing nasal polyp size and the severity of symptoms, improve disease-specific quality of life, and to have an acceptable safety profile. This study aims to present long-term follow-up data on disease-specific sinonasal outcomes of patients with CRSwNP who have been treated with dupilumab for up to 3 years in a real-world setting.
METHODS: Retrospective review of electronic medical records of a single Canadian rhinology center evaluating disease-specific sinonasal outcomes that are routinely collected for clinical care. This study included all patients who received dupilumab for the treatment of CRSwNP and who had completed at least one follow-up visit. The Sino-Nasal Outcome Test (SNOT)-22 was used to evaluate treatment symptom improvement.
RESULTS: Ninety-nine patients started dupilumab therapy during the study period. The mean SNOT-22 at the start of therapy was 61.1 (±22.91) At the time of the review, 65 patients had completed 1 year of therapy, 40 had completed 2 years of therapy, and 18 had completed 3 years of therapy. The mean SNOT-22 score at these timepoints was 16.75 (±13.86), 15.02 (±14.40), and 10.22 (±11.56), respectively.
CONCLUSION: This real-world study shows that in patients with CRSwNP treated with dupilumab, improvement in disease-specific quality of life seen after 1 year continues and can be maintained at 3 years of treatment.
Purpose/Aim of the study: Since chalcones belong to the flavonoid family, the effects of a new synthetic chalcone derivative on memory, chronic stress, and expression of hippocampal BDNF gene were studied.Materials and methods: In this experiment, the male wistar rats were placed under restraint stress (6 h/day) for 21 days and then treated with a newly synthesized chalcone, containing methoxy on the aromatic rings or vehicles (20 mg/kg, intraperitoneal, IP). After the behavioral Passive avoidance, Open field, and Morris water maze tests, the levels of serum corticosterone (CORT) and hippocampal brain-derived neurotrophic factor (BDNF) were analyzed.Results: Results of these tests presented significant differences between the Stress (St) and Chalcone (Ch) groups. Chronic stress led to high CORT levels and impaired memory functions. Moreover, a single dose of synthetic chalcone in the St group could postpone memory impairments. Furthermore, a 20 mg/kg IP injection of chalcone markedly attenuated the decrease of hippocampal BDNF.Conclusions: It has been already proposed that flavonoids have beneficial effects on different types of memory. According to these results, further investigations are required to explore other factors besides BDNF that could be acutely modulated by chalcones.
<P>PROBLEM TO BE SOLVED: To provide a detergent medicinal form removing both oily stains and aqueous stains with one agent.  <P>SOLUTION: The detergent contains (1) a monofatty acid ester of a polyglycerol and (2) one or two or more kinds of fatty acid soaps. A fatty acid ester of the polyglycerol having characteristics as a hydrophilic surfactant is preferred as the fatty acid ester of the polyglycerol, concretely a form having 5-15 average degree of polymerization of the glycerol and at least ≥4, preferably 8-10 free hydroxy groups present therein is preferred. A decaglycerol skeleton is especially preferred. A lauric acid residue, a myristic acid residue, a palmitic acid residue, a stearic acid residue, a behenic acid residue, an oleic acid residue, an isostearic acid residue, etc., can preferably be exemplified as the fatty acid residue. The lauric acid residue is especially preferred.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PCT No. PCT/FR93/00151 Sec. 371 Date Nov. 14, 1994 Sec. 102(e) Date Nov. 14, 1994 PCT Filed Feb. 12, 1993 PCT Pub. No. WO93/17113 PCT Pub. Date Sep. 2, 1993The present invention relates to a nucleotide sequence characterized in that it is selected amongst the following nucleotide sequences: the sequence of the gene coding for a B-lactamase, or any part of said gene, particularly the sequence between nucleotides 1 and 394 containing the signals for expression of the gene, or the coding sequence comprising nucleotides 395 to 1274, or any sequence hybridizing under stringent conditions with the above sequence. Utilization of B-lactamase as a carrier protein for carrying heterolog epitopes for the preparation of vaccine compositions is also disclosed.
A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in a patient's blood vessels is provided. A chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive substance is administered at sites of the plaques. The chemical composition comprises one or more of d-limonene, propylene glycol, octanoic acid, 2-octane, glycerine, acetylsalicylic acid, acetic acid, omega-3 fatty acids, ethanol, methanol, ezetimibe, rosuvastatin, resveratrol, lactic acid, gluconic acid, chloroform, carbon disulfide, dichloromethane, toluene, lauryldimethyl hydroxysultaine, and any combination thereof. The chemical composition enables modification of plaques by altering their composition. The modification comprises partial dissolution, complete dissolution, or elimination of the plaques, and makes the plaques amenable to different forms of plaque treatment. The modified plaques are eliminated from the patient's body. The modification or elimination of the plaques facilitates treatment of cardiovascular diseases caused due to plaques formed in the blood vessels.
A pyretic arthralgia pill is the latest product which is specially used to treat rheumatoid arthritis in the present invention. Pyretic arthralgia is one type of rheumatoid arthritis. Causes of pyretic arthralgia are undecided. It is a chronic systematic disease with arthritis pathological changes, mostly occurs in young adults, and is slowly severe. The product is prepared from coix seeds, radix paeoniae rubrathe, rhizoma atractylodis, cassia twig, Poria cocos and notopterygium root. The product has functions of dispelling wind, disinhibiting dampness, promoting circulation of blood, promoting defensive qi, securing the skin and exterior, nourishing qi of middle-jiao energy, inspiring clear qi, removing sore-toxin and inducing urination. Therefore, for migratory arthralgia symptoms which belong to rheumatoid arthritis, the product can play a role in dehumidifying and easing pain if taken.